Retatrutide simultaneously targets three hormone receptors—GIP, GLP-1, and glucagon—producing a 24.2% body weight reduction at the maximum 12-mg weekly dose over 48 weeks. This triple mechanism circumvents metabolic resistance by combining incretin-mediated appetite suppression with glucagon-driven energy expenditure. Nearly two-thirds of participants achieved clinically significant weight loss exceeding 20%, while diabetic patients saw HbA1c drop by 2.02 percentage points, with 27% reaching normal glucose levels.
This represents a paradigm shift in obesity pharmacotherapy. The 23.2% fat mass reduction rivals bariatric surgery outcomes without surgical risks, while the 82.4% reduction in hepatic fat addresses the growing epidemic of fatty liver disease. The systemic benefits—8.79 mmHg blood pressure reduction and improved kidney function markers—suggest retatrutide could become a cornerstone therapy for cardiovascular-kidney-metabolic syndrome. However, this remains a comprehensive review of Phase 2 data rather than new primary research. The real test lies in upcoming Phase 3 trials and long-term safety data, particularly regarding the noted chronotropic effects that require cardiac monitoring.